Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
0.4546+0.0170 (+3.88%)
At close: 04:00PM EDT
0.4600 +0.01 (+1.19%)
After hours: 07:41PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close0.4376
Open0.4300
Bid0.4501 x 1000
Ask0.4600 x 2900
Day's Range0.4200 - 0.4599
52 Week Range0.3100 - 1.4800
Volume359,477
Avg. Volume730,738
Market Cap68.069M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.2730
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adamis Pharmaceuticals Corporat
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Skyworks soars, Big Biopharma builds immunity to headwinds, and Baidu and the cloud; and Harmonic Drive Systems, Elekta, and Nabtesco.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • GlobeNewswire

    Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

    DSMB Has Reviewed Interim Clinical and Safety Data and Recommended that the Study ContinueSAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced that a meeting of the Data Safety Monitoring Board (DSMB) overseeing the Company’s Phase 2/3 clinical trial investigating the use of Tempol for the tre

  • Zacks

    What Makes Adamis (ADMP) a New Buy Stock

    Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • GlobeNewswire

    Adamis Appoints Vickie Reed to Board of Directors

    New Director Named with Significant Executive Management and Financial Leadership ExperienceSAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of directors. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertis

Advertisement
Advertisement